Sellas: Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

 - SLS009 Demonstrated Promising Efficacy in Phase 1 Study with 36.4% Clinical Response (ORR) in r/r Peripheral T-cell Lymphomas (PTCL); ORR in r/r PTCL Patients with Standard of Care is 25.8% -

- One Patient with Complete Metabolic Response Continuing Treatment for over 62 weeks and another patient with Complete Response by CT Continuing Treatment for over 24 weeks -

- Phase 1b/2 Study in PTCL Ongoing with top line data expected in 1H 2024 -

https://www.biospace.com/article/releases/sellas-receives-fda-orphan-drug-designation-for-sls009-for-treatment-of-peripheral-t-cell-lymphomas/